For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Lilly to Expand Japan Business via Alliances with Subsidiaries in Other Asian Countries
May 2, 2011
- Mitsui to Acquire Mercian's Pharma and Chemicals Business
May 2, 2011
- Drug Price Listings to Be Delayed One Month: Korosho
May 2, 2011
- OECD Japan Report Calls For Restraint in Social Security Spending
May 2, 2011
- JMA to Propose Postponing Revision of Medical, Nursing Fees
May 2, 2011
- Xyzal Ranked No. 1 in GP Market in February: RepTrack Survey
May 2, 2011
- Members of JMA Board of Trustees Disagree on Resolution to Postpone Revisions
May 2, 2011
- The Great East Japan Earthquake: MRs in the Disaster Zone
May 2, 2011
- Nat'l Consensus Needed on Drugs' Cost-effectiveness Assessment: Prof. Endo
May 2, 2011
- Wakamoto's Mid-term Management Plan Calls For Return to Black in FY2011
May 2, 2011
- Korosho to Introduce Relief Program for Families of Patients Who Die due to Anticancer Drug-related Adverse Effects
May 2, 2011
- Meiji Seika Pharma Aims at Sales of ¥200 Bil. in FY2020
May 2, 2011
- Wakamoto to Set Up JV for Generics with Taiwan Drugmaker
May 2, 2011
- HSC Approves Draft Report on Measures against Rheumatism
May 2, 2011
- Moratorium on Copayment by Quake Victims to Be Extended: Korosho
May 2, 2011
- Kyowa Kirin Completes Legal Procedures for Acquisition of ProStrakan
May 2, 2011
- Chugai's Pegasys Granted Priority Review Status for CHB
May 2, 2011
- Outgoing KEIZAI DOYUKAI Chairman Expresses Hope for His Successor from Regulation-bound Industry
May 2, 2011
- Kaken to Achieve Its Operating Profits Goal: Mizuho Securities
May 2, 2011
- Gov't Designates Eribulin as Ad-restricted Drug
May 2, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…